PAG
MRKR icon

Private Advisor Group’s Marker Therapeutics MRKR Stock Holding History

Private Advisor Group’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,380
Closed -$125K – 1495
2018
Q3 		$125K Buy
+1,380
New +$118K ﹤0.01% 1527

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Private Advisor Group's MRKR Position: Q4 2018 in Review

Private Advisor Group sold out of Marker Therapeutics (MRKR) in Q4 2018, closing a stake of 1,380 shares — an estimated $125K sold.

Private Advisor Group first reported a position in MRKR in Q3 2018 and held it in 1 quarter. The position peaked at $125K in Q3 2018. 43 funds tracked by Wall St. Rank hold MRKR as of Q4 2018.

  • Private Advisor Group reported no remaining Marker Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Private Advisor Group sold 1,380 Marker Therapeutics shares in Q4 2018, an estimated $125K.
  • Private Advisor Group first reported a position in Marker Therapeutics in Q3 2018 and held it in 1 quarter.
  • Private Advisor Group's Marker Therapeutics position peaked at $125K in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2018.

Based on Private Advisor Group's 13F filing for Q4 2018, filed 11 Feb 2019.